Results of IMpassion132 study are negative. Early relapsed TNBC remain an unmet clinical need. Special thanks to Sara Tolaney for presenting our COMPASS-TNBC platform trial study, which is exploring innovative therapies for these patients. Gustave Roussy Barbara Pistilli

Dr. Sara Tolaney (Sara Tolaney) discusses the results and practice impact from the phase II DOLAF trial, the IMpassion 132 phase III trial and the MORPHEUS phase Ib/II study in today's #ESMObreast24 Proffered Paper Session 1. #BreastCancer #bcsm

Why was IMpassion132 negative? And what’s the path forward for improving outcomes in early recurrent TNBC? Great discussion by Sara Tolaney (Sara Tolaney), recapitulating the current status & future hopes for one of the most challenging presentations of breast cancer. #ESMOBreast24

Rebecca Dent presents IMp132 at #ESMOBreast24 . No OS ⬆️ by adding atezo to chemo for pts with early relapsed TNBC. Unfortunate results, highlighting the huge unmet need represented by these pts. A lot will be learned from the trial samples. Concomitant 📰: annalsofoncology.org/article/S0923-…

All is said by Dr Rebecca Dent :

“Rapidly relapsing TNBC remains a critical research priority and clinical unmet need”.

Patients currently receive most treatment options in the (neo)adjuvant setting. We urgently need better treatment strategies

#ESMOBreast24 #ESMOAmbassadors

A pleasure to co-host the latest ESMO Open podcast with Giuseppe Curigliano - Paolo Tarantino
Dana-Farber Harvard University Università degli Studi di Milano G Curigliano MD PhD ESMO Open
oncodaily.com/64477.html

#BreastCancer #Cancer #ESMO #Oncology #OncoDaily

#ESMOBreast24 :Personalised #PrecisionMedicine for early #BreastCancer : Individualised assessment of initial response to therapy may pave the way for chemotherapy-sparing treatment
👇Read Nadia Harbeck’s opinion in #ESMODailyReporter
ow.ly/5saO50RGQ9E

#ESMOBreast24 : New insights into the evolution of #BreastCancer for better prevention and detection of high-risk women. Read the #ESMODailyReporter article 📌ow.ly/Q21y50RH4bZ

Carmen Criscitiello approaching several controversies in the real world oncology in BRCA/HR+ adjuvant scenario
▪️How to choose between CDKi and PARPi?
▪️ Are CDKi less effective in BRCAmut?
▪️ Can we combine at least sequentially CDKi and PARPi?
#ESMOBreast24 #ESMOAmbassadors

#ESMOBreast24 📍Hamburg hall - Clinical trials design: Novel designs session

Tomás Pascual presents different biomarker-enrichment strategies and illustrates them with examples of conducted clinical trials

#ESMOBreast24 #ESMOAmbassadors ESMO - Eur. Oncology

Great start #ESMOBreast24 with highly interesting talks on clinical trial design with stellar panel🤩 Sara Tolaney Tatiana Prowell, MD Stefan Michiels OncoAlert

#ESMOBreast24
💫Prof. #HelenaEarl take on adjuvant therapy for patients with #TNBC after primary systemic and local treatment
Carmen Criscitiello Erika Hamilton, MD ESMO - Eur. Oncology
⁩ #ESMOAmbassadors #bcsm

#ESMOBreast24 📍Hamburg hall - Clinical trials design: Novel designs session

Tatiana Prowell, MD provides her take on the ideal endpoint for neoadjuvant trials in breast cancer

#ESMOAmbassadors
Erika Hamilton, MD Matteo Lambertini, MD PhD G Curigliano MD PhD Carmen Criscitiello Evandro de Azambuja, MD, PhD Pablo Mando

#bcsm

Terrific presentation by Sara Tolaney at #ESMOBreast24 , recapitulating 10+ years of de-escalation trials and novel frontiers for the tailoring of treatment in early-stage breast cancer, including promising biomarkers such as HER2DX, PET response and MRD. #ESMOAmbassadors #bcsm

Dear #BCSM Twitter,
Dr Yara Abdou’s account that 2.2K of you were following got hacked and repurposed by a dude as @ PgambarRaj. Please unfollow, report, and block this pretending hacker.

Then follow the new Dr Yara Abdou at Yara Abdou

It’s not nice to steal & lie, friends.

Impressive continuous growth for ESMO Breast, with >3000 participants and >600 submitted abstracts!

#ESMOBreast24 already buzzing and the conference doesn't start for 20 minutes.

Join us in Berlin Hall at 1pm for the opening lecture!

ESMO - Eur. Oncology
#bcsm
Sarah Cannon Docs

Very intriguing talk by Nadia Harbeck on therapy adaptation and personalized medicine in early Breast cancer at the #ESMOBreast24 in Berlin. ESMO - Eur. Oncology OncoAlert Omar Abdihamid Oncologist @Garissa Cancer Center

Here we go! Everything ready #ESMOBreast24 #ESMOAmbassadors Matteo Lambertini, MD PhD G Curigliano MD PhD Philippe Aftimos, MD  Paolo Tarantino Evandro de Azambuja, MD, PhD Kevin Punie Erika Hamilton, MD Carmen Criscitiello

Dr. Sara Tolaney (Sara Tolaney) will chair the #ESMOBreast24 Pfizer Industry Satellite Symposium on strategic sequencing in 3L HER2+ #MetastaticBreastCancer on May 15th at 11:30 CEST.
She will also discuss the treatment landscape of HER2+ #MBC 👇👇👇
cslide.ctimeetingtech.com/breast24hybrid…